Print

Synageva BioPharma (GEVA) Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares  
1/9/2013 9:40:44 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced the closing of a $118 million underwritten public offering of 2,472,500 shares of common stock, including 322,500 shares of common stock which were issued pursuant to the exercise of the underwriters’ option to purchase additional shares, at a price of $47.53 per share.
//-->